Characterizing the Effect of Dopamine on Markers of Lymph Re-circulation in Fontan-associated Protein-losing Enteropathy
Megadott ok: Inadequate patient enrollment
A legfontosabb adatok
- Hol
- Ann Arbor (Egyesült Államok)A helyszín megnézése
Helyszínek itt: Egyesült Államok
- University of Michigan Health SystemAnn Arbor, Egyesült ÁllamokNo longer taking part
A vizsgálat adatai
- Ki végzi
- University of Michigan
- Azonosító
- NCT03322345
- A regiszteradat frissítve
- 2026. július 14.
- Eredeti leírás
Patients that have undergone a Fontan procedure (surgical correction for single ventricle congenital heart disease) may develop a complication known as protein-losing enteropathy (PLE). Some studies suggest PLE is primarily caused by impaired lymph flow. Use of continuous dopamine infusion can improve PLE. Evidence suggests the effect of dopamine may be through its effect on lymphatic function. This observational study looks at markers of lymph flow and PLE symptoms after treatment using dopamine and other standard therapies during disease exacerbations.A teljes eredeti leírásKevesebb
Patients that have undergone a Fontan procedure (surgical correction for single ventricle congenital heart disease) may develop a complication known as protein-losing enteropathy (PLE). Some studies suggest PLE is primarily caused by impaired lymph flow. Use of continuous dopamine infusion can improve PLE. Evidence suggests the effect of dopamine may be through its effect on lymphatic function. This observational study looks at markers of lymph flow and PLE symptoms after treatment using dopamine and other standard therapies during disease exacerbations.
Bevonási feltételek: Males and females with Fontan physiology of any age; Must have protein losing enteropathy with current worsening who require additional therapies; Participant consent or parental/guardian consent and participant assent.
Kizáró feltételek: Patients with inflammatory bowel disease (i.e Crohn's, ulcerative colitis); Patients with systemic autoimmune disease (i.e. Systemic Lupus Erythematous); Patients with primary immunodeficiency syndromes; Patients with nephrotic syndrome; Patients with anemia; Patients less than 31 pounds.